ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026
Evaluation of the Hemoglobin, Albumin, Lymphocyte, and Platelet Score and Inflammatory Markers in Preterm Premature Rupture of Membranes.
Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
problemTo evaluate the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and its relationship with inflammatory markers in patients with preterm premature rupture of membranes (PPROM), and to assess their association with gestational age and neonatal outcomes. METHOD OF STUDY: This retrospective study included 226 pregnant women diagnosed with PPROM between 24 and 34 weeks of gestation between 2023 and 2026. Patients were categorized according to gestational age at diagnosis as early PPROM (24 + 0 to < 32 + 0 weeks) and late PPROM (32 + 0 to 34 + 0 weeks). Demographic, clinical, and laboratory data were collected, including C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The HALP score was calculated using routine laboratory parameters. Receiver operating characteristic (ROC) analysis was performed to evaluate the ability of the HALP score and inflammatory markers to identify early PPROM. Multivariate logistic regression analysis was used to identify independent predictors of adverse neonatal outcomes.
resultsPatients in the early PPROM group delivered at significantly earlier gestational ages, had lower birth weights, and had longer latency periods than those in the late PPROM group (all p < 0.001). Inflammatory markers, including CRP, NLR, PLR, and SII, were higher in the early PPROM group, whereas hemoglobin, lymphocyte levels, and HALP scores were lower (all p < 0.05). Adverse neonatal outcomes were more frequent in the early PPROM group than in the late PPROM group (53.5% vs. 20.6%, p < 0.001). ROC analysis demonstrated that CRP had the highest diagnostic performance (AUC: 0.663), followed by SII and NLR, whereas HALP showed modest discriminative ability (AUC: 0.632). In multivariate analysis, only gestational age at diagnosis was identified as an independent predictor of adverse neonatal outcome.
conclusionThe HALP score and inflammatory markers were associated with earlier gestational age at PPROM diagnosis, suggesting a relationship with inflammatory and immunonutritional status. However, their ability to predict adverse neonatal outcomes was limited, and gestational age remained the primary determinant of neonatal prognosis. Therefore, HALP may be considered a complementary biomarker rather than a standalone prognostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.